Generation of effective immune responses requires expansion of rare antigen-specific CD4 + T cells. The magnitude of the responding population is ultimately determined by proliferation and survival. Both processes are tightly controlled to limit responses to innocuous antigens. Sustained expansion occurs only when innate immune sensors are activated by microbial stimuli or by adjuvants, which has important implications for vaccination. The molecular identity of the signals controlling sustained T-cell responses is not fully clear. Here, we describe a prominent role for the Notch pathway in this process. Coactivation of Notch allows accumulation of far greater numbers of activated CD4 + T cells than stimulation via T-cell receptor and classic costimulation alone. Notch does not overtly affect cell cycle entry or progression of CD4 + T cells. Instead, Notch protects activated CD4 + T cells against apoptosis after an initial phase of clonal expansion. Notch induces a broad antiapoptotic gene expression program that protects against intrinsic, as well as extrinsic, apoptosis pathways. Both Notch1 and Notch2 receptors and the canonical effector RBPJ (recombination signal binding protein for immunoglobulin kappa J region) are involved in this process. Correspondingly, CD4 + T-cell responses to immunization with protein antigen are strongly reduced in mice lacking these components of the Notch pathway. Our findings, therefore, show that Notch controls the magnitude of CD4 + T-cell responses by promoting cellular longevity.
CD4 T cell | cell death | Delta | Bcl-2 | Fas T he precursor frequency of naive CD4 + T cells specific for individual peptide antigens is low, necessitating expansion for effective defense against microbial invaders. This process is tightly regulated to prevent harmful responses to noninfectious selfantigens. Efficient induction of proliferation requires ligation of the T-cell receptor (TCR), as well as costimulatory signals (1) , such as those generated by interaction of CD28 molecules on T cells with CD80/CD86 molecules on antigen presenting cells (APCs). A major additional checkpoint lies in the ability to keep activated T cells alive after clonal expansion, as was shown by monitoring T-cell responses to isolated protein antigens (1, 2) . Lacking signatures of microbial danger, such antigens elicit weak responses attributable to death of the responding T cells after normal initial expansion. Responses to protein antigens can be boosted by the use of adjuvants, which induce signals that allow activated T cells to survive. The nature of these signals is not fully known (3) , and their identification would improve our ability to rationally design vaccination strategies.
Death of activated CD4 + T cells can be induced via an extrinsic pathway, via Fas/CD95-mediated activation of caspase 8, which, in turn, activates effector caspases (4) . An intrinsic apoptosis pathway also exists, in which release of cytochrome c from mitochondria into the cytosol leads to activation of effector caspases. Cytochrome c release depends on Bax and Bak proteins and is inhibited by antiapoptotic proteins, such as Bcl-2, Bcl-XL, and Mcl-1 (5).
These latter factors are themselves antagonized by proapoptotic molecules such as Bim (Bcl-2 interacting mediator of cell death), Puma (p53 upregulated modulator of apoptosis), and Noxa (also known as phorbol-12-myristate-13-acetate inducible protein). The relative levels of all these proteins determine the fate of the cell (5) . The intrinsic apoptosis pathway controls contraction of the antigen responsive CD4 + T-cell pool after clearance of infection (4, 6) . Death of CD4 + T cells activated in the absence of adjuvant also depends on this intrinsic pathway with critical roles for Bim and, to a lesser extent, Puma (3, 4, 6) . The extrinsic pathway may contribute to cell death under these conditions when antigen levels are high (7) .
The Notch cell surface receptor controls proliferation and survival of many cell types. Signaling by Notch involves cleavage within its transmembrane region by a γ-secretase complex (8) . This allows the intracellular domain of Notch (NICD) to translocate to the nucleus, where it activates transcription together with the DNA binding factor RBPJ [recombination signal binding protein for immunoglobulin kappa J region, also known as CSL (CBF1, Suppressor of Hairless, Lag1)] and the MAML (mastermind-like) coactivator (8) . Five canonical ligands for Notch exist, called Jagged1, Jagged2, Delta1 (DLL1), Delta3 (DLL3), and Delta4 (DLL4), which (except for DLL3) activate the same Notch signaling pathway (8) .
Expression of Notch ligands is induced on APCs by microbial products and by CD4 + T cells, supporting a role for this pathway in control of T-cell responses (9) (10) (11) . Indeed, Notch regulates differentiation of CD4 + T helper cells (12) . Conflicting reports exist about the role of Notch in CD4 + T-cell expansion. Some studies concluded that Notch stimulates proliferation of CD4 + T cells; others found it to be inhibitory (13) (14) (15) (16) (17) . Notch may have distinct roles in CD4 + T cells under different conditions, but some of the reported discrepancies might stem from experimental factors. For instance, some studies targeted the γ-secretase, which does not selectively affect cleavage of Notch only, but also of other substrates (15) (16) (17) (18) . Also, antibody-mediated activation of Notch may not faithfully mimic the function of natural ligands (15) . Finally, high expression of the active intracellular domain of Notch or the use of high concentrations of recombinant ligands may activate pathways not normally regulated by Notch (13, 14) . Here, we have revisited the role of Notch on expansion of CD4 + T cells. To avoid potential issues of specificity, we complemented gain of function with the use of genetic deficiencies in the Notch pathway. We found that activation of Notch strongly boosts CD4 + T-cell responses by inducing an antiapoptotic program after initial clonal expansion. Correspondingly, CD4 + T-cell responses to protein antigens in vivo are much reduced in mice with deficiencies in the Notch pathway. Thus, our results show that Notch promotes the size of the activated CD4 + T-cell response by extending cellular longevity.
Results
Notch Ligands Promote CD4 + T-Cell Responses. The consequences of Notch signaling on T cells may depend on their developmental stage (19) . We, therefore, used purified naïve CD62L + CD44 − CD4 + T cells (depleted of NK cells, NK T cells, regulatory T cells, and activated T cells) for our experiments. Much greater numbers of viable activated CD4 + T cells could be recovered from cultures using DLL4-expressing APCs than from cultures using control APCs (Fig. 1A ). This was true despite the presence of activating antibodies to CD28 in all cultures, suggesting that Notch signals complement classical costimulatory signals.
Ectopic expression of ligands for Notch may lead to lateral activation of Notch in the APC, leading to production of factors that promote expansion of CD4 + T cells indirectly. To exclude this, we activated naive CD4 + T cells with recombinant Notch ligands in the absence of APCs. DLL4-Fc strongly promoted recoveries of viable CD4 + T cells compared with control-Ig cultures ( Fig. 1B and C, Right). DLL1-Fc also augmented the yields from CD4 + T-cell cultures, albeit less potently than DLL4-Fc (Fig. 1C ). Thus, DLL ligands enhance CD4 + T-cell responses through direct effects on CD4 + T cells.
Notch Protects Activated CD4 + T Cells Against Cell Death. Stimulation with DLL might enhance cell cycle entry, the rate of proliferation or survival. DLL4-Fc did not change the proportion of carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled CD4 + T cells that failed to divide after 2 d of culture, suggesting that Notch activation does not affect the threshold for cell cycle entry ( Fig. 2A and Fig. S1 ). Furthermore, similar populations had divided once or twice at this time point, regardless of the presence of DLL4-Fc ( Fig. 2A and Fig. S1 ), and cell cycle distribution patterns of cells activated for 2 or 3 d in the presence of DLL4-Fc or control-Ig were indistinguishable ( Fig. 2B ). Production of IL-2 was also not affected by DLL4-Fc ( Fig. S2 ). Thus, DLL4-Fc did not affect general T-cell activation or proliferation. Indeed, CD4 + T-cell expansion was similar during the first 3 d of culture ( Fig. 2C ). In sharp contrast, at later time points, DLL4-Fc promoted survival of cells that had already divided ( Fig. 2 A and C). After 5 d, the majority of CD4 + T cells in control cultures had died, whereas most cells stimulated with DLL4-Fc were still alive ( Fig. 2A ). Addition of Q-VD-OPh (QVD), a broad-spectrum caspase inhibitor, almost completely rescued survival of CD4 + T cells activated with control-Ig to the levels obtained by DLL4-Fc ( Fig. 2D ), suggesting that DLL4-Fc protects activated CD4 + T cells from apoptosis. Deficiency for Fas/CD95, the receptor involved in the extrinsic apoptosis pathway (4), rescued a proportion of cells activated in the presence of control-Ig. Such deficiency did not, however, further increase the viable cell yields from DLL4-Fc cultures ( Fig. 2E ). This suggests that DLL4-Fc protected cells that would have succumbed to Fas/CD95-mediated killing in the absence of Notch activation. Importantly, recoveries from cultures of Fas/CD95-deficient CD4 + T cells could still be enhanced twofold by stimulation with DLL4-Fc ( Fig. 2E ), demonstrating that this ligand also induces protection against cell death mediated by mechanisms not involving Fas/CD95. These results suggest that Notch induces protection against both extrinsic and intrinsic apoptosis pathways.
Elements of the Notch Pathway Involved. T-cell-specific genetic deficiency for Notch1 or Notch2 resulted in decreased, but measurable responses to DLL4-Fc ( Fig. 3 A and B) . Responsiveness was lost entirely when CD4 + T cells lacked expression of both Notch1 and Notch2 (Fig. 3C) , showing that these two receptors function redundantly to regulate longevity of CD4 + T cells. Although expression of Notch3 and Notch4 is induced in CD4 + T cells after activation (9, 13) , combined deficiency for these receptors did not affect survival in response to DLL4-Fc ( Fig.  3D ). Finally, DLL4-Fc-mediated survival was entirely dependent on RBPJ (Fig. 3E ). Thus, both the Notch1 and the Notch2 receptors relay survival signals through the canonical Notch signaling pathway.
Notch Induces a Survival Program. Although activation of Notch induces protection against the extrinsic apoptosis pathway, neither expression of Fas (CD95) nor of its ligand (CD178) was reduced by stimulation with DLL4-Fc ( Fig. 4A ). DLL4-Fc did modestly increase cell surface expression of CD25, the high affinity IL-2 receptor α-chain ( Fig. 4A ), but not of the IL-2/IL-15 receptor β-chain (CD122), the common cytokine receptor γ-chain (CD132) or the IL-7 receptor α-chain (CD127) (Fig. 4A ). The elevated expression of CD25 in DLL4-Fc stimulated cells could allow stronger IL-2 receptor signaling and activate survival pathways. However, IL-2 can also increase the sensitivity of activated CD4 + T cells to the extrinsic apoptosis pathway (20) . Indeed, addition of exogenous IL-2 to control cultures reduced viable CD4 + T-cell numbers (Fig. S3 ). Stronger IL-2 receptor signaling is, thus, unlikely to explain the superior survival induced by DLL4-Fc, suggesting the existence of other protective mechanisms.
Because RBPJ is required to induce survival of CD4 + T cells (Fig. 3E ), a transcriptional mechanism is likely involved. We, therefore, prepared RNA from cells activated with control-Ig or DLL4-Fc. RNA was isolated just before cells started dying in control-Ig cultures (3 d after activation; Fig. 2C , Right) to minimize indirect effects caused by different viability between samples. Using a multiplex assay, we measured mRNA expression of members of the Bcl-2 family (which inhibit the intrinsic apoptosis pathway), c-FLIP (cellular FLICE-like inhibitory protein, an inhibitor of the extrinsic pathway, encoded by Cflar), and the inhibitor of apoptosis (IAP) family [X-linked (X)IAP, in particular, blocks apoptosis via both intrinsic and extrinsic pathways] (4). Among these genes, only expression of Bcl-2 was significantly induced and this translated into elevated Bcl-2 protein ( Fig. 4 B and C and Figs. S4 and S5 ). Retroviral expression of Bcl-2 rescued CD4 + T cells activated with control-Ig (Fig. 4D ). However, protection was less strong than obtained by expression of NICD1 ( Fig. 4D ), suggesting the activation of additional protective pathways by Notch. One candidate is the IκB family protein Bcl-3, which protects activated CD4 + T cells against cell death (3, 21) . Indeed, DLL4-Fc induced expression of Bcl-3, and retroviral expression of Bcl-3 rescued cells activated with control-Ig from death ( Fig. 4 B and D) . Again, however, this effect was less pronounced than the protection provided by expression of NICD1.
Because neither Bcl-2 nor Bcl-3 expression achieved the strong antiapoptotic effects of Notch activation, we conducted genomewide transcriptional profiling. We made use of the rotation testing using mean ranks (ROMER) method for gene-set enrichment analysis (22) , using gene sets representing biological pathways (C2) or gene ontology categories (C5) from MSigDB (http://www. broadinstitute.org/gsea/msigdb/). DLL4-Fc stimulation led to enrichment of multiple gene sets related to apoptosis (Table S1 and Datasets S1, S2, S3, and S4). Furthermore, stimulation with DLL4-Fc resulted in enrichment for gene sets associated with metabolic, biosynthetic, and stress response pathways (Table S1 and Datasets S1, S2, S3, and S4), which may all impact cellular survival.
DLL4-Fc induced expression of a number of genes, previously described to protect T cells from apoptosis (Fig. 4E ). For example, deficiency for the Ets-1 transcription factor (23) or the β-arrestin adaptor protein (encoded by Arrb1) (24) compromised survival of mature CD4 + T cells. Transgenic expression of IEX-1 (immediate early gene on X-radiation 1) (encoded by Ier3) protected CD4 + T cells against superantigen-mediated depletion (25) , and both IEX-1 and Faim3 (Fas apoptotic inhibitory molecule 3) inhibited susceptibility of T cells to CD95/Fas-mediated apoptosis induction (25, 26) . The Pim1 (Proviral Integration site for the Moloney murine leukemia virus) kinase and the TNF receptor-associated factor (TRAF)5 adapter were found to control survival of activated CD8 + T cells (27, 28) . Likewise, the GILZ (Glucocorticoid Induced Leucine Zipper) transcription factor (encoded by Tcs22d3) protected T-cell lines from apoptosis induced by cytokine withdrawal or TCR stimulation (29, 30) , and Ddit4 (31) inhibited dexamethasone-induced death of thymocytes. Finally, costimulation with DLL4-Fc elevated both mRNA and cell surface levels of ICOS (inducible T-cell costimulator) ( Fig. 4 E and F) , a receptor implicated in control of CD4 + effector cell survival (32) . In summary, Notch activates a broad gene expression program to protect activated CD4 + T cells from cell death. Because of the diversity of protective mechanisms induced, ectopic expression of individual factors may never achieve the level of protection elicited by Notch.
Notch Determines the Magnitude of CD4 + T-Cell Responses in Vivo.
To test whether Notch protects activated CD4 + T cells from cell death in the context of antigen presentation by genuine APC, we used TCR transgenic T cells lacking expression of RBPJ or both Notch1 and -2. RBPJ-deficient CD4 + T cells (expressing the OTII TCR, specific for ovalbumin peptide in I-A b ) expanded to the same degree as wild-type (WT) CD4 + T cells in response to presentation of protein antigen by dendritic cells (Fig. 5 ). However, whereas most WT CD4 + T cells were viable after 5 d of culture, most RBPJ-deficient CD4 + T cells had died by this time (Fig. 5 ). Similar findings were obtained with CD4 + T cells deficient for both Notch1 and Notch2 (using the AND TCR specific for pigeon cytochrome c peptide in I-E k ) (Fig. S6) . Therefore, also when activated by professional APCs, CD4 + T cells depend on Notch for their survival after initial expansion. We reasoned that this requirement might result in reduced responses of CD4 + T cells isolated from Notch-deficient mice at the peak of a primary response after immunization, because fewer antigen-specific cells would persist to be reactivated. To test this, we immunized mice with T-cell-specific deletions in both Notch1 and Notch2 genes with keyhole limpet hemocyanin (KLH) adsorbed to alum. Responses of Notch1/Notch2 double-deficient CD4 + T cells were significantly weaker than those elicited in WT mice (Fig. 6A) . Although alum is a clinically relevant adjuvant (33) , it is not a natural adjuvant associated with microbial pathogens. To test the role of Notch in the context of a natural adjuvant, we immunized mice with a mixture of KLH mixed and extract of the eggs of the helminth parasite Schistosoma mansonii (SEA). This extract elicits responses both to antigens present in the extract (Fig. 6B, Right) as well as to the KLH model antigen (Fig. 6B, Left) . Importantly, responses to both types of antigens were markedly reduced in mice lacking expression of Notch1 and Notch2 in T cells (Fig. 6B ). On the other hand, no defect was observed upon immunization of mice lacking only Notch1 or Notch2 (Fig. 6C) . Finally, CD4 + Tcell responses were strongly reduced in mice lacking expression of RBPJ (Fig. 6D) . Thus, the magnitude of the CD4 + T-cell response after immunization with protein antigens and different adjuvants depends on Notch1, Notch2, and canonical Notch signaling.
Discussion
The ability of the immune system to combat large numbers of microbes, while limiting responses to innocuous antigens, requires tight regulation of the magnitude of antigen responsive CD4 + T-cell populations. Our findings show that Notch controls the size of this population, predominantly by protecting already expanded clones from apoptosis.
The antiapoptotic activity of Notch in primary CD4 + T cells depends on RBPJ, suggesting that a transcriptional mechanism is involved. Whether nontranscriptional mechanisms are also involved, based on reported physical interactions of the NICD with factors such as XIAP, Bax, Nur77, p56Lck, and PI3K remains to be tested (34) (35) (36) . Notch induces a transcriptional program, with protective activities against both extrinsic and intrinsic apoptosis pathways. Thus, the extrinsic pathway is inhibited by Faim3, IEX-1, and TRAF5 (25) (26) (27) . For Faim3, this may involve inhibition of caspase 8 recruitment and diversion of Fas/CD95 signaling toward survival pathways (37) . On the other hand, Bcl-2, Bcl-3, and β-arrestin inhibit the intrinsic apoptosis pathway by preventing Bax/Bak multimerization, release of Bim and inducing expression of the Bcl2 gene, respectively (3, 6, 21, 24, 38) . How other induced factors fit into this scheme is less clear. The leucine zipper transcription factor GILZ may inhibit the intrinsic as well as the extrinsic pathway by repressing the Bim, Fas, and FasL genes (29, 30) . The Pim1 kinase inhibits the intrinsic pathway by inactivating the proapoptotic Bad protein and stimulates cellular metabolism (39) , which helps cells cope with the metabolic demands during rapid proliferation. That Notch stimulates metabolic pathways is supported further by the enrichment for gene sets associated with carbohydrate, lipid and glucose metabolism, glucose transport, biosynthesis, and generation of energy (Table S1 and Datasets S1, S2, S3, and S4). Although previous studies found Notch to induce expression of Bcl-XL (36, 40) , neither mRNA nor protein levels for this Bcl-2 family member were induced by DLL4-Fc (Figs. S4 and S7). Also, we did not find evidence for increased expression of Bmi1 (Fig. S8 ) or decreased expression of Noxa (Fig. S4) (19) .
The requirement for specific signals that license CD4 + T-cell expansion helps restrict the generation of aggressive immune responses to those antigens that merit such potentially harmful activity. Adjuvants elicit the production of signals licensing the survival of activated CD4 + T cells even to noninfectious protein antigens (1, 2) . Notch protects activated CD4 + T cells at precisely the stage controlled by adjuvants, making it a candidate receptor for this licensing function. In support of this, microbial adjuvants induce expression of several Notch ligands on APCs (9, 11) and Notch, like adjuvants, induces a protective program, which includes Bcl-3 (3, 21, 38) . Interestingly, Notch also promotes expansion of CD8 + T cells, in part, by protecting these cells from cell death, although in these cells Notch also seems to enhance proliferation itself (Fig. S9 ). Thus, Notch has a general role in controlling the viability of activated T cells.
In conclusion, our results demonstrate that Notch activates multiple pathways that protect activated CD4 + T cells against apoptosis. This function of Notch is essential for the generation of full-blown CD4 + T-cell responses upon immunization. Thus, Notch, a conserved decider of cell fate, has been adopted by the immune system to determine whether the presence of antigen deserves the generation of an aggressive immune response.
Materials and Methods
Reagents. Antibodies and cytokines are listed in Table S2 . QVD was purchased from R&D (catalog no. OPH001). Human Fc-tagged DLL1 and DLL4 protein was produced in HEK293T cells transfected with expression plasmids for DLL1-Fc or DLL4-Fc (41) . For isolation procedure, see SI Materials and Methods. Isotype-matched control-Ig (palivizumab; Synagis no. 54874TF) was a gift from AIMM Therapeutics.
Vectors and Constructs. Bcl-2 was cloned into the MSCV-Thy1.1 vector using BglII and SalI. Bcl-3-MSCV-Thy1.1 and NICD1-MSCV-Thy1.1 were described before (9, 21) .
Cell Culture. Cells were grown in Iscove's modified Dulbecco's medium (IMDM) with 10% (vol/vol) FCS, 2 mM GlutaMAX (Invitrogen), 100 U/mL penicillin (Invitrogen), 100 μg/mL streptomycin (Invitrogen), and 50 μM βmercaptoethanol.
Mice. Six-to 8-wk-old C57BL/6NCrl mice were purchased from Charles River. Notch1 flox, Notch2 flox, Notch3 null, Notch4 null, RBPJ flox, CD4-Cre transgenic, and Fas lpr mice (for origins, see SI Materials and Methods) were backcrossed to C57BL/6 mice for over 10 generations. Littermate controls were used. Cre + mice heterozygous for floxed alleles or homozygous WT behaved as Cre − mice. Mice were maintained in under specific pathogen free conditions. Animal experiments were in compliance with the European Union and national laws and approved by the local ethical committee.
CD4 T-Cell Activation. Naïve CD44 − CD62L + CD49b − CD25 − (Thy1.2 + ) CD4 + T cells were purified from spleen and peripheral lymph nodes using anti-CD4 microbeads (Miltenyi; catalog no. 130-049-201) and FACS. A total of 5 × 10 4 naïve CD4 + T cells were cultured with 1 μg/mL anti-CD28 in 96-well flat bottom plates coated with 10 μg/mL anti-CD3 and 5 μg/mL DLL4-Fc, DLL1-Fc, or control-Ig or with 2.5 × 10 4 irradiated A20 cells (120 Gy) expressing DLL4 or empty vector, 1 μg/mL anti-CD28, and different amounts of anti-CD3. Also, 5 × 10 4 naïve CD4 + T cells were cultured with 5 × 10 4 dendritic cells (DCs), purified from spleen by magnetic activated cell sorting (MACS) using anti-CD11c beads (Miltenyi 130-052-001), and ovalbumin protein (50 μg/mL). Viability and cell numbers were analyzed by flow cytometry using AnnexinV-APC (BD Biosciences; 550474) and 7-amino-actinomycinD (7AAD) (eBioscience; 00-6993-50). For labeling with CFSE (Sigma; 21888), naïve CD4 + T cells were washed with cold PBS and stained for 5 min at room temperature with 5 μM CFSE at 2 × 10 6 cells/mL in PBS, followed by washing with PBS (1% BSA). Retroviral Transductions. Virus was produced in PlatE cells as described (9) . CD4 + T cells (activated 36 h earlier) were spin-infected (700 × g for 90 min at 37°C) with viral supernatant (with 8 μg/mL polybrene), followed by 2.5 h at 37°C.
Cell Cycle Analysis. Activated CD4 + T cells were stained with 10 μM Draq5 (Biostatus) in medium for 30 min at 37°C and analyzed by flow cytometry. Cell cycle distribution was analyzed with the cell cycle tool (FlowJo) using the Watson (pragmatic) model.
Microarray Analysis and Quantitative RT-PCR. RNA was extracted using TRIzol, followed by RNeasy columns (Qiagen) from CD4 + T cells 3 d after activation. RNA was labeled and hybridized by the W. M. Keck Facility (Yale Center for Genome Analysis) on Mouse BeadChip (Illumina) mouse whole-genome expression arrays (MouseRef-8 v2.0). Two pairs of samples are replicates from one experiment, the third pair comes from an independent experiment. For statistical analysis, see SI Materials and Methods. cDNA was made with Oligo (dT) and random hexamers using the first Strand cDNA synthesis kit (Fermentas). Quantitative PCR using SYBRgreen (Bio-Rad) was performed using the C1000 Thermal Cycler (Bio-Rad). Relative concentrations were determined based on standard curves and normalization for β-actin using the Bio-Rad CFX Manager software. Melt curves ensured amplification of a single product. For PCR primers, see Table S3 .
Immunization. Mice were immunized s.c. with 50 μg of KLH in alum, KLH with SEA (300 μg), or SEA alone. (For preparation of SEA, see SI Materials and Methods.) After 8 d, CD4 + T cells were isolated from draining lymph nodes and stimulated in vitro with splenic APCs and different concentrations of KLH or SEA. 
